Adalimumab-induced Epstein-Barr virus-related lymphoproliferative disorder on FDG PET/CT Journal Article


Authors: Ward, J.; Noy, A.; Ulaner, G.; Riedl, C.
Article Title: Adalimumab-induced Epstein-Barr virus-related lymphoproliferative disorder on FDG PET/CT
Abstract: Adalimumab is a fully human chimeric tumor necrosis factor inhibitor used to treat immune-mediated disorders such as psoriatic arthritis. We present a 51-year-old woman with psoriatic arthritis on methotrexate and infliximab for 12 years. Adalimumab replaced infliximab because of worsening symptoms. Following 3 doses administered 1 week apart, rapidly enlarging cervical lymph nodes developed. Biopsy revealed Epstein-Barr virus-related polymorphic lymphoproliferative disorder. 18F-FDG PET/CT demonstrated widespread hypermetabolic lymphadenopathy; follow-up at 5 weeks off adalimumab revealed almost complete resolution of this adenopathy. This is most consistent with Epstein-Barr virus-related lymphoproliferative disorder secondary to tumor necrosis factor α inhibition. © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Keywords: 18f-fdg pet/ct; adalimumab; epstein barr virus-related lymphoproliferative disorder
Journal Title: Clinical Nuclear Medicine
Volume: 43
Issue: 5
ISSN: 0363-9762
Publisher: Lippincott Williams & Wilkins  
Date Published: 2018-05-01
Start Page: 344
End Page: 345
Language: English
DOI: 10.1097/rlu.0000000000002054
PROVIDER: scopus
PUBMED: 29538028
DOI/URL:
Notes: Article -- Export Date: 1 May 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Christopher Riedl
    60 Riedl
  2. Gary Ulaner
    147 Ulaner
  3. Ariela Noy
    352 Noy